<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00783484</url>
  </required_header>
  <id_info>
    <org_study_id>B0831001</org_study_id>
    <nct_id>NCT00783484</nct_id>
  </id_info>
  <brief_title>A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects</brief_title>
  <official_title>A Double-Blind (3rd Party Open), Placebo-Controlled, Crossover, Dose Escalating Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539, To Assess The Potential Of PF-03716539 To Inhibit CYP3A4 (In Vivo) And To Evaluate The Drug Interaction Potential Between PF-03716539 And Darunavir Or Maraviroc In Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      First in human study to evaluate the safety, tolerability, and pharmacokinetics of
      PF-03716539. The potential of PF-03716539 to increase the concentrations of midazolam,
      darunavir and maraviroc will also be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of escalating single oral doses of PF 03716539 administered as Extemporaneous Powder for Solution (EPS) in healthy adult subjects.</measure>
    <time_frame>27 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To explore the pharmacokinetics of escalating single oral doses of PF 03716539 in healthy adult subjects.</measure>
    <time_frame>6 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the potency of PF 03716539 for CYP3A4 inhibition utilizing single dose IV midazolam as a probe substrate for CYP3A4/5.</measure>
    <time_frame>6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the potential of PF 03716539 to enhance or &quot;boost&quot; the pharmacokinetics of both darunavir and maraviroc.</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-03716539 crossover, single dose escalation (doses subject to change).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-03716539 crossover, single dose escalation (doses subject to change).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Midazolam-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Darunavir-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maraviroc-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maraviroc-PF-03716539 drug-drug interaction (PF-03716539 200 mg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03716539</intervention_name>
    <description>PF-03716539 10 mg oral solution, single dose</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03716539</intervention_name>
    <description>PF-03716539 25 mg oral solution, single dose</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03716539</intervention_name>
    <description>PF-03716539 3 mg oral solution, single dose</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for 3 mg, 10 mg and 25 mg of PF-03716539 (single dose)</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03716539</intervention_name>
    <description>PF-03716539 100 mg oral solution, single dose</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03716539</intervention_name>
    <description>PF-03716539 200 mg oral solution, single dose</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03716539</intervention_name>
    <description>PF-03716539 50 mg oral solution, single dose</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for 50 mg, 100 mg and 200 mg of PF-03716539 (single dose)</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Midazolam 1 mg IV, single dose</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam + PF-03716539 (100 mg)</intervention_name>
    <description>Midazolam 1 mg IV, single dose plus PF-03716539 100 mg oral solution, single dose</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam + PF-03716539 (50 mg)</intervention_name>
    <description>Midazolam 1 mg IV, single dose plus PF-03716539 50 mg oral solution, single dose</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <description>Darunavir 600 mg tablet twice daily for 9 days (Days 1-9)</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir + PF-03716539</intervention_name>
    <description>Darunavir 600 mg tablet, single dose plus PF-03716539 50 mg oral solution, single dose (Day 10)</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc</intervention_name>
    <description>Maraviroc 150 mg tablet once daily for 6 days (Days 1-6)</description>
    <arm_group_label>Cohort 5</arm_group_label>
    <other_name>Selzentry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc +PF-03716539</intervention_name>
    <description>Maraviroc 150 mg tablet, single dose plus PF-03716539 100 mg oral solution, single dose (Day 7)</description>
    <arm_group_label>Cohort 5</arm_group_label>
    <other_name>Selzentry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc</intervention_name>
    <description>Maraviroc 225 mg tablet once daily for 6 days (Days 1-6)</description>
    <arm_group_label>Cohort 6</arm_group_label>
    <other_name>Selzentry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc +PF-03716539</intervention_name>
    <description>Maraviroc 225 mg tablet, single dose plus PF-03716539 200 mg oral solution, single dose (Day 7)</description>
    <arm_group_label>Cohort 6</arm_group_label>
    <other_name>Selzentry</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive.

        Body Mass Index (BMI) of approximately 18 to 30 kg/m2. Total body weight &gt;50 kg (110 lbs).

        Exclusion Criteria:

        Pregnant or nursing females. females of childbearing potential. Evidence or history of
        clinically significant hematological, renal (including kidney stones), endocrine,
        pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic
        disease (including drug allergies, but excluding untreated, asymptomatic, seasonal
        allergies at time of dosing) or clinical findings at screening.

        Treatment with an investigational drug within 30 days (or determined by the local
        requirement, whichever is longer) or 5 half-lives preceding the first dose of study
        medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B0831001&amp;StudyName=A%20Study%20To%20Evaluate%20The%20Safety%2C%20Tolerability%20And%20Pharmacokinetics%20Of%20Single%20Oral%20Doses%20Of%20PF-03716539%20In%20Healthy%20Adult%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2008</study_first_submitted>
  <study_first_submitted_qc>October 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <last_update_submitted>May 28, 2009</last_update_submitted>
  <last_update_submitted_qc>May 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>First in Human (FIH), PF-03716539, PK enhancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

